Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Excessive Ca2+ currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg2+, NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca2+ determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg2+ and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg2+, tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone is a new, noncompetitive NMDAR antagonist 475 that exhibits fast antidepressant-like action by improving performance of rats in the forced swim test. 476”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [475]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical research found that REL-1017 preferentially binds to the NR1-2D subunit [182]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“NP_015566 corresponds to the NR1-1a splice variant [42] lacking the N1 cassette but including C1 and C2 cassettes.”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“REL-1017 (esmethadone HCl; dextromethadone HCl), the d-isomer of racemic methadone, is a low-affinity, low-potency, uncompetitive NMDAR channel blocker, devoid of meaningful opioid agonist effects [12] with experimental evidence for producing brain-derived neurotrophic factor (BDNF) and target of rapamycin complex 1 (…”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Fava, M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
Self-citationStahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Pani, L., Guidetti, C., Folli, F. B., de Somer, M., Traversa, S., Inturrisi, C. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012196 · Cited by 24
Self-citationCooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 23
Self-citationFava, M., Stahl, S. M., Pani, L., Martin, S. D., Cutler, A. J., Maletic, V., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Kosten, T. R., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15265 · Cited by 18
Self-citationClinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 17
Donello, J. E., McIntyre, R. S., Pickel, D. B., & Stahl, S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020157 · Cited by 15
Self-citationKlein, A. K., Austin, E. W., Cunningham, M. J., Dvořák, D., Gatti, S., Hulls, S. K., Kiss, L. L., Kruegel, A. C., Marek, G. J., Papp, M., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01783-1 · Cited by 15
Comai, S., Martin, S. D., Mattarei, A., Guidetti, C., Pappagallo, M., Folli, F. B., Alimonti, A., & Manfredi, P. L. (2024) · Pharmaceuticals · doi:10.3390/ph17121618 · Cited by 14
Self-citationMehra, A., Khanna, J., Singh, G., Sachdeva, V., & Bedi, N. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-025-00308-y · Cited by 10
Misiachna, A., Konecny, J., Kolcheva, M., Ladislav, M., Prchal, L., Netolický, J., Kortus, Š., Zahumenska, P., Langore, E., Novak, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117201 · Cited by 8
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 9
A synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Ferri, N., Martin, S. D., Stuart, J., Traversa, S., Mattarei, A., Comai, S., Folli, F. B., Pappagallo, M., Guidetti, C., Inturrisi, C. E., et al. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00477-3 · Cited by 6
Self-citationJiang, C., Wang, C., Qu, W., Wang, Y., Wang, H., Wei, X., Wang, M., He, Q., Wang, Y., Yuan, L., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21743 · Cited by 6
Pappagallo, M., Kosten, T. R., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Martin, S. D., Comai, S., Mattarei, A., Inturrisi, C. E., & Manfredi, P. L. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02621-6 · Cited by 5
Self-citationGalli, A., Moretti, S., Dule, N., Cairano, E. S. D., Castagna, M., Marciani, P., Battaglia, C., Bertuzzi, F., Fiorina, P., Pastore, I., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2024 · Cited by 5
Self-citationColognesi, M., Shkodra, A., Gabbia, D., Kawamata, H., Manfredi, P. L., Manfredi, G., & Martin, S. D. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1384829 · Cited by 5
Self-citationFerri, N., Martin, S. D., Stuart, J., Traversa, S., Folli, F. B., Pappagallo, M., O’Gorman, C., Guidetti, C., Mattarei, A., Inturrisi, C. E., et al. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00450-6 · Cited by 3
Self-citationWallach, J. V., Cameron, S., Dybek, M. B., Stanley, B., Orme, C., Riad, N., Kavanagh, P. V., Brandt, S. D., Knapp, A., Gamrat, J. M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02700 · Cited by 2
Banzato, M., Furlan, A., Locatelli, P., Sgrignani, J., Ongaro, A., Dolmella, A., Martin, S. D., Comai, S., Cavalli, A., Inturrisi, C. E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02605 · Cited by 2
Self-citationKonecny, J., Misiachna, A., Chvojková, M., Kletečková, L., Kolcheva, M., Novak, M., Prchal, L., Ladislav, M., Hemelíková, K., Netolický, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116981 · Cited by 2
Guidetti, C., Papakostas, G. I., Stahl, S., Pani, L., Martin, S. D., Mattarei, A., Comai, S., Kröger, C., Champasa, P., Gorodetzky, C. W., et al. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000618 · Cited by 2
Self-citationBano, S., Khan, A. U., Ali, K., Rehman, B., Khattak, A., Zeb, A., Zhang, X., Ullah, A., & Khan, S. A. (2026) · ChemistrySelect · doi:10.1002/slct.202502811 · Cited by 1
Mercadante, S. (2026) · CNS Drugs · doi:10.1007/s40263-026-01329-1 · Cited by 1
Levinstein, M. R., de Oliveira, P. A., Casajuana-Martín, N., Quiroz, C., Budinich, R. C., Rais, R., Rea, W. P., Ventriglia, E. N., Llopart, N., Casadó-Anguera, V., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02864-3 · Cited by 1
Kolcheva, M., Netolický, J., Misiachna, A., Rybalko, N., Zahumenska, P., Doderovic, J., Pakhomova, A., Sanctis, C. V. D., Schneider, G. K., Hemelíková, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.06.756690
Metadata
- Authors
- Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., Bifari, F., Cavalli, A., Alimonti, A., Pani, L., Fava, M., Traversa, S., Folli, F., & Manfredi, P. L.
- Affiliations
- Aptuit (Italy) (IT)
- University of California San Diego (US)
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
- University of Padua (IT)
- Institute for Research in Biomedicine (CH)
- Albert Einstein College of Medicine (US)
- Relmada Therapeutics, Inc. (United States) (US)
- University of Milan (IT)
- SIB Swiss Institute of Bioinformatics (CH)
- University of Modena and Reggio Emilia (IT)
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
- Corresponding author
- Manfredi, Paolo L.
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-08-13
- Volume
- 15
- Issue
- 8
- Pages
- 997
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9414551
- OpenAlex
- W4291512787
- Cited by
- 31
- References
- 48
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 7 · 2022: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- ETH Zürich Research Collection
- Funders
- Relmada Therapeutics (VDD9974)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- NMDA receptor antagonists, major depressive disorder, dextromethorphan, memantine, ketamine, MK-801, calcium current, open channel conformation, drug binding affinity, psychotomimetic side effects, glutamate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.